Biogen Idec, Eisai sign multi-drug deal in the area of Alzheimer's disease
Executive Summary
To further enhance its strong neurodegenerative disease pipeline, Biogen Idec Inc. will co-develop and co-commercialize two of Eisai Co. Ltd.'s Alzheimer’s disease candidates--the Phase II-ready ß-site amyloid precursor protein cleaving enzyme (BACE) inhibitor E2609 and Phase II BAN2401, an anti-amyloid beta (Aß) antibody. In addition, Eisai has the option to jointly develop and commercialize two of Biogen’s AD candidates--the Phase Ib Aß antibody BIIB037 and preclinical BIIB076, an anti-tau monoclonal antibody.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice